Trade Desk Inc vs Zimmer Biomet Holdings Inc — how do they compare? Trade Desk Inc trades at $13.45 (market cap $6.37B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.9× Trade Desk Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| TTD | ZBH | |
|---|---|---|
Market Cap | $6.37B | $18.55B |
Sector | Technology | Health |
52-Week High | $55.36 | $107.71 |
52-Week Low | $13.39 | $79.58 |
Enterprise Value | $5.32B | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
The Trade Desk (TTD) stock trades at $13.39, down 2.97% today and near 52-week lows after a sharp 90% decline from its 2024 peak. Recent Q2 2026 earnings missed expectations with 3% revenue growth and weak Q3 guidance, triggering analyst downgrades. Technical indicators are bearish, with support at $12. The company maintains strong profitability margins but faces growth deceleration and competitive pressures in digital advertising.
Outlook remains cautious due to execution gaps and macroeconomic headwinds. While valuations appear reasonable with a P/E of 16.14, near-term risks from revenue declines and advertiser pullbacks outweigh potential upside. Investors should monitor Q3 earnings for signs of stabilization before considering entry.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →